Genexine, Inc. (095700.KQ) KOE
Currency In KRW
- General
- Statistics
- Historical Data
- Profile
- Financials
Genexine, Inc.
Address
Korea Bio Park Building B
Seongnam, 13488
Korea (the Republic of)
Phone
82 3 1628 3200
Website
Sector
Healthcare
Industry
Biotechnology
Employees
86
First IPO Date
September 15, 2009
Key Executives
| Name | Title | Pay | Year Born |
| Jaehyun Choi | Head of R&D | 0 | N/A |
| Jang Hee Lee | EVP of Operations | 0 | N/A |
| Jongsoo Lee | Senior Manager of IR & PR | 0 | N/A |
| Chul Jun Hyun | Auditor & Director | 0 | N/A |
| Jong Sup Park | Chief Medical Officer | 0 | N/A |
| Jungwon Woo | President & Director | 0 | N/A |
| Young-Chul Sung | Founder & Chairman of the Scientific Advisory Board | 0 | 1956 |
| Ki Yong Kim | SVP of Bio Research Institute | 0 | N/A |
| Sung-June Hong | Executive Vice President, Chief Financial Officer & Director | 0 | 1965 |
| Hyun Jin Park | EVP of Corporate Development | 0 | N/A |
| Neil K. Warma | President & Director | 0 | 1963 |
Description
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
